A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)

Trial Profile

A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Posaconazole (Primary) ; Posaconazole (Primary) ; Voriconazole; Voriconazole
  • Indications Aspergillosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 16 Jul 2018 to 16 Jul 2019.
    • 26 Apr 2017 Planned primary completion date changed from 16 Jul 2018 to 16 Jul 2019.
    • 24 Mar 2017 This trial has been completed in Greece.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top